Navigation Links
Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
Date:4/21/2011

ANN ARBOR, MICH. -- A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.

Almost 1,000 patients who had advanced, hormone-refractory prostate cancer were given up to 36 weeks of chemotherapy with docetaxel and prednisone. These patients were randomized so that one half got an additional pill with a dose of atrasentan while the other half got a placebo pill. Patients who completed their chemotherapy and showed no progression of the disease were given the option of continuing the additional blinded pill (atrasentan or placebo).

The study's DSMC evaluated a planned interim analysis of trial data and determined the evidence indicating no benefit from the drug was strong enough to close the study early rather than waiting another 18 months as was originally planned. The DSMC did not find evidence that the drug was harming patients.

New patient enrollment to the study stopped in April 2010 and few patients continue to take the study pill. Patients still taking study medication should speak to their doctor about stopping safely and what to do with their remaining pills. Treatment assignment is being unblinded, so patients can learn from their study doctor whether they took atrasentan or a placebo.

The study ("S0421: Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer") was supported by the National Cancer Institute (NCI) and was conducted by SWOG (formerly the Southwest Oncology Group) with the participation of several other NCI cooperative groups.

Atrasentan for the trial was provided under an agreement with Abbott Laboratories and was distri
'/>"/>

Contact: Frank DeSanto
fdesanto@umich.edu
734-998-0114
University of Michigan Health System
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NHGRI charts course for the next phase of genomics research
2. Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
3. Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting
4. Phase I trial indicates ponatinib may thwart most resistant CML
5. Assessing positive outcomes of phase III trials
6. Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
7. Nutrition rating enhancing front-of-package nutrition rating systems and symbols: Phase 1
8. New Phase II study shows first-line promise of lung cancer drug PF-299
9. Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer
10. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
11. Front-of-package symbols and systems: IOM phase 1 report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Texas (PRWEB) November 26, 2014 ... and Distinguished Teaching Professor in the Department ... recently discussed facial fat compartments, fat grafting, and ... The Meeting," an annual conference held by the ... and intricacies of this underlying facial structure were ...
(Date:11/26/2014)... News) -- New regulations to reduce emissions of the ... issued Wednesday by the U.S. Environmental Protection Agency. ... premature death. The new rules would lower the ... billion to between 65 to 70 parts per billion, ... line with the latest science will clean up our ...
(Date:11/26/2014)... 26, 2014 The Maryland Economic ... the tenth annual MEDA Awards, which, sponsored by ... in Maryland. “The MEDA Awards recognize the individuals, ... the state. We encourage our members to nominate ... a positive economic impact in the state of ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 The ... as the Association’s new director of meetings and ... Association’s annual meeting, special events and conferences. ... to this post,” said AAA Executive Director Ed ... of enthusiasm and energy. She was recognized in ...
(Date:11/26/2014)... Loffler Companies has been selected as a 2014 ... information and news publication for resellers of imaging technology, ... Loffler has earned this prestigious award and the seventh ... honor the best and the brightest in the imaging ... chosen for their innovative marketing and sales programs, community ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 2Health News:Dr. Rod J. Rohrich Discusses Facelifts at ASPS Annual Assembly 3Health News:EPA Issues Tougher Rules on Ozone Emissions 2Health News:EPA Issues Tougher Rules on Ozone Emissions 3Health News:Maryland Economic Development Association Seeking Submissions for 2015 Awards 2Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2
... angioplasty, but not everyone agrees , , FRIDAY, Sept. 14 ... can best treat patients with the chest pain called ... drugs while others vote for surgery. , The results ... Revascularization and Aggressive Drug Evaluation (COURAGE), seemed to indicate ...
... GLENDALE HEIGHTS, Ill., Sept. 14 The Board ... GLOV), a distributor and,supplier of disposable gloves and ... markets, today announced it would file a,Form 15 ... Securities and Exchange,Commission to deregister the Company,s common ...
... -- The Center of Excellence in Environmental Toxicology ... has been awarded $2.3,million over the next four ... smoke. The grant is part of the National,Institutes ... The GEI represents a unique collaboration between geneticists ...
... The following statement,is being released by Sr. ... the Catholic Health Association of the United States ... for the clarification provided,today by the Holy See,s ... provision of artificially administered nutrition and,hydration to patients ...
... Nancy G. Brinker, Leader of the Global Breast Cancer Movement, Takes New ... ... Nancy G.,Brinker, founder of Susan G. Komen for the Cure, the world,s largest ... at the White House. Ambassador Brinker is expected to be,sworn in today and ...
... DIEGO, Sept. 14 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ... investor reception during the 43rd Annual Meeting of the ... September 19,2007 at 4:30 a.m. PT / 1:30 p.m. ... presentation will be webcast, and recordings will be made,available ...
Cached Medicine News:Health News:Doctors Debate Drugs vs. Surgery for Angina 2Health News:Doctors Debate Drugs vs. Surgery for Angina 3Health News:Doctors Debate Drugs vs. Surgery for Angina 4Health News:AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange 2Health News:Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure 2Health News:Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure 3Health News:Comment Regarding Congregation for the Doctrine of Faith Clarification Concerning Nutrition and Hydration for Patients in a Persistent Vegetative State 2Health News:President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol 2Health News:President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol 3Health News:President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol 4
(Date:11/26/2014)... Nov. 26, 2014 Scott Steiger lives in ... the world. As an engineer for the past 20 years, he,s ... the military service. He,s been to six of the seven continents. ... Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... he has a pretty good idea of what,s required. ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... 26, 2014 The medical magnetic resonance ... of 4%, with world market revenues for 2013 ... and other types of medical imaging have led ... numerous medical conditions in children and adults, each ... report, Medical Imaging Markets , analyzes the ...
Breaking Medicine Technology:Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... Drafted Perform at Similar Level as Those Without ReconstructionLAS ... at the 2009 American Orthopaedic Society of Sports Medicine ... collateral ligament (UCL) reconstruction prior to selection in the ... risk of future injury or affect the rate of ...
... experience does not always keep hands injury-freeLAS VEGAS, Feb. ... have been on the rise in recent years, with ... United States. Many of those injuries might be prevented ... today at the 2009 Annual Meeting of the ...
Cached Medicine Technology:Elbow Ligament Reconstruction Appears Not to Affect Future Professional Advancement in Baseball 2Experience Not Always the Best Prescription for Snowblowers 2Experience Not Always the Best Prescription for Snowblowers 3Experience Not Always the Best Prescription for Snowblowers 4
... The Plume-inator produces the ... family of smoke evacuators. ... test button, hospital grade plug, ... and dual purpose swing ring ...
A system for the removal and filtration of laser and surgical smoke....
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
... The PS Medical Strata valve is ... the resistance properties of the valve can ... is designed to minimize overdrainage of cerebrospinal ... within a normal physiologic range, regardless of ...
Medicine Products: